Dendritic cell therapy with CD137L-DC-EBV-VAX in locally recurrent or metastatic nasopharyngeal carcinoma is safe and confers clinical benefit.

ABSTRACT:

Introduction

Epstein-Barr virus (EBV) is associated with nasopharyngeal carcinoma (NPC), and provides a target for a dendritic cell (DC) vaccine. CD137 ligand (CD137L) expressed on antigen presenting cells, costimulates CD137-expressing T cells, and reverse CD137L signaling differentiates monocytes to CD137L-DC, a type of DC, which is more potent than classical DC in stimulating T cells.

Methods

In this phase I study, patients with locally recurrent or metastatic NPC were administered CD137L-DC pulsed with EBV antigens (CD137L-DC-EBV-VAX).

Results

Of the 12 patients treated, 9 received full 7 vaccine doses with a mean administered cell count of 23.9 × 10⁶ per dose. Treatment was well tolerated with only 4 cases of grade 1 related adverse events. A partial r

SUBMITTER: Nickles E 

PROVIDER: S-EPMC10991364 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature